达格列净对2型糖尿病患者血压影响的系统评价(4)
[13] Kaku K,Inoue S,Matsuoka O,et al.Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control:a phaseⅡ multicentre,randomized,double-blind,placebo-controlled trial[J].Diabetes Obes Metab,2013,15(5):432-440.
[14] Kohan D E,Fioretto P,List J,et al.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment[J].J Am Soc Nephrol,2011,22(Suppl):232A-233A.
[15] Ljunggren O,Bolinder J,Johansson L,et al.Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab,2012,4(11):990-999.
[16] Calado J.Dapagliflozin,an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus[J].Drugs,2009,12(12):785-798.
[17] Francis J,Zhang J,Farhi A,et al.A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria[J].Nephrol Dial Transplant,2004,19(11):2893-2895.
[18] Sowers J R,Epstein M,Frohlich E D.Diabetes,hypertension,and cardiovascular disease:an update[J].Hypertension,2001,37(4):1053-1059.
[19] Paromita K,Ian P,Richard D.The UK Prospective Diabetes Study(UKPDS):clinical and therapeutic implications for type 2 diabetes[J].Br J Clin Pharmacol,1999,48(5):643-648.
(收稿日期:2014-12-30) (本文编辑:欧丽), http://www.100md.com(陈丽等)
[14] Kohan D E,Fioretto P,List J,et al.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment[J].J Am Soc Nephrol,2011,22(Suppl):232A-233A.
[15] Ljunggren O,Bolinder J,Johansson L,et al.Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab,2012,4(11):990-999.
[16] Calado J.Dapagliflozin,an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus[J].Drugs,2009,12(12):785-798.
[17] Francis J,Zhang J,Farhi A,et al.A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria[J].Nephrol Dial Transplant,2004,19(11):2893-2895.
[18] Sowers J R,Epstein M,Frohlich E D.Diabetes,hypertension,and cardiovascular disease:an update[J].Hypertension,2001,37(4):1053-1059.
[19] Paromita K,Ian P,Richard D.The UK Prospective Diabetes Study(UKPDS):clinical and therapeutic implications for type 2 diabetes[J].Br J Clin Pharmacol,1999,48(5):643-648.
(收稿日期:2014-12-30) (本文编辑:欧丽), http://www.100md.com(陈丽等)